ArticlePloS one2015

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

Cian M McCrudden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.